End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
6.69 CNY | +0.90% | +2.61% | -6.95% |
Apr. 19 | UBS Upgrades China's 2024 GDP Growth Forecast | MT |
Apr. 03 | Winning Health Technology Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The group's high margin levels account for strong profits.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- With an enterprise value anticipated at 3.64 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Revenue estimates are regularly revised downwards for the current and coming years.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: IT Services & Consulting
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.95% | 1.96B | C- | ||
-9.73% | 200B | A- | ||
+2.14% | 168B | B+ | ||
+11.81% | 167B | B- | ||
+6.07% | 101B | A- | ||
+8.17% | 77.28B | A- | ||
-6.51% | 71.13B | A | ||
+18.16% | 69.94B | C- | ||
-23.80% | 49.16B | C | ||
+1.40% | 47.6B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 300253 Stock
- Ratings Winning Health Technology Group Co., Ltd.